Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.99%
1,093.81
+10.77
+0.99%
—1,083.041,082.631,099.011,080.59——
SIXC
Communications
SIXC
Communications
SIXC
+1.06%
608.77
+6.39
+1.06%
—602.38602.38609.75599.75——
SIXE
Energy
SIXE
Energy
SIXE
+0.96%
1,254.81
+11.98
+0.96%
—1,242.831,229.311,258.881,220.51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2.76%
1,761.11
+47.29
+2.76%
—1,713.821,715.471,763.111,715.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.40%
642.58
+2.59
+0.40%
—639.99636.98644.04631.81——
SIXR
Staples
SIXR
Staples
SIXR
+1.63%
851.13
+13.67
+1.63%
—837.46840.30852.55840.30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.76%
217.98
+3.76
+1.76%
—214.22214.22218.25214.05——
SIXT
Technology
SIXT
Technology
SIXT
+0.23%
3,211.83
+7.45
+0.23%
—3,204.383,215.043,217.443,159.90——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.55%
948.98
+23.60
+2.55%
—925.38927.91949.76927.91——
SIXV
Health care
SIXV
Health care
SIXV
+2.20%
1,474.52
+31.81
+2.20%
—1,442.711,443.011,477.901,443.01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.30%
2,392.12
+30.78
+1.30%
—2,361.342,391.002,399.182,354.52——
HELP:NASDAQ
Cybin Inc
$5.31
+8.15%
(+0.40) 1D
$5.35
+0.75% (+0.040)
Pre-market
Closed: Apr 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HELP...
Open
$4.97
High
$5.33
Low
$4.92
Avg. vol.
1.13M
Volume
323.00
52-wk high
$8.97
52-wk low
$4.29
Beta
1.03
Shares outstanding
50.04M
No. of employees
50
News stories
From sources across the web
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines. The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010. As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development. In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc
CEO-
Employees50
Founded2019
HeadquartersToronto, Ontario, Canada
SectorPharmaceutical industry
Websitecybin.com
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
18.97M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
12.21M
Operating expense
-
-
-
33.24M
Total operating expenses
-
-
-
33.24M
Operating income
-
-
-
-33.24M
Other non operating income
-
-
-
-28.00K
EBT including unusual items
-
-
-
-30.58M
EBT excluding unusual items
-
-
-
-30.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-28.00K
Net income
-
-
-
-30.58M
Net profit margin
-
-
-
-
Earnings per share
-0.76
-2.86
-0.53
-1.46
Interest and investment income
-
-
-
1.44M
Interest expense
-
-
-
-
Net interest expenses
-
-
-
1.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-33.19M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer